. This is shown in CLL where a proportion of patients have paraproteins derived from the neoplastic clone (Leonard et al., 1979) . Equally B cell leukaemia, not obviously different from that seen in CLL may occur in some patients with FCC lymphomas (Galton et al., 1978; Garrett et al., 1979 (Lowe et al., 1981) . The polyclonal antisera were produced in the Immunodiagnostic Research Laboratory of the same department. In addition monoclonal antibody UCHT-1 which detects the T3 antigen, a panperipheral T associated molecule, was a kind gift from Dr Peter Beverley (Beverley & Callard, 1981 ). An anti-HLA-DR a chain antibody 19/48 was a kind gift from Dr G. Brown. Peanut agglutinin, prepared by Dr Raykundalia as described by Rose et al. (1981) , was also coupled to ox red cells.
The direct antibody rosette test is a very sensitive assay for measuring surface membrane antigens. It is particularly useful for detecting the low levels of surface membrane immunoglobulin (SmIg) classically associated with CLL (Dhaliwal et al., 1978 (Stathopoulos & Elliott, 1974) .
Lymphocytes were prepared as above. Rosettes were made by centrifuging the lymphocyte and red cell suspensions at 250 g for 5 min and incubating the pellet at 4°C for 3 h. The rosettes were resuspended gently by placing on a 15rpm rotor. The cells were not pre-treated in this study with neuraminidase, a procedure which stabilises spontaneous rosettes (Bentwich et al., 1973) . However, sheep red cells were pretreated with 2% S-2-Amino-ethylisothiouronium salt (AET) for 15 min to increase the strength of rosettes (Kaplan & Clark, 1974) .
Absolute lymphocyte numbers were calculated from a total white cell count (blood collected in sequestrene) and a differential count performed on a blood sample collected at the same time as that used for marker studies. Phagocytic cells were identified by their ingestion of rhodamine-labelled opsonised yeasts which were distinguishable under a fluorescence microscope from the leucocyte nuclei which were labelled with acridine orange. The proportions of non-phagocytic mononuclear cells forming rosettes was determined in suspension in counting chambers.
Results

B cell leukaemia
The number of blood lymphocytes expressing SmIg was determined in 186 untreated patients with histologically classified B cell neoplasia and 15 healthy controls. These values are plotted against the ratio of blood lymphocytes expressing kappa to those expressing lambda in Figure 1 (a-f). The absolute B cell numbers in the healthy control group fell within the range of 0.12-0.7 x 1091-1.
The K: A ratio for the group ranged between 2.67 and 0.8. Different histopathological groups of B cell neoplasms showed marked differences from the normal and from each other. In ML-BCLL all but one of the patients showed evidence of B cell leukaemia, as defined by having more than 0.75 x 109 B lymphocytes I`with either >90% expressing kappa or > 80% expressing lambda. In patients with low grade FCC tumour a third pattern was apparent. Sixty-five patients were included in this group. Fifty-nine had mixed centrocytic-centroblastic lymphoma and 6 centrocytic lymphoma. Eighteen of the patients had B lymphopenia. Twenty of the group had overt B cell leukaemia. Most of these patients with B cell leukaemia had B lymphocyte counts of <10 x iO1 F' and eight had total lymphocyte counts within the normal range. The leukaemic B cells in these patients, in general, resemble the morphological spectrum associated with CLL. Although centrocytes were identifiable in the blood in a proportion of both aleukaemic and leukaemic patients they were usually present as a minor fraction. Occasionally patients were seen where the majority of leukaemic cells were centrocytes. Of the six patients with pure centrocytic lymphoma analysed, one had B cell leukaemia.
Lymphoplasmacytoid tumours were associated with a similar spectrum of blood B cell profiles to that seen in FCC tumours; i.e. about a third had B cell leukaemia, a third had B cell lymphopenia and a third had a normal number of B cells.
In high grade lymphoma, B cell lymphopenia was a feature in over half the cases. Three of the 22 patients in this group had B cell leukaemia. This group comprised 9 patients with centroblastic lymphoma, 5 with immunoblastic lymphoma and 8 unclassifiable cases with high grade lymphoma.
Ig isotypes on leukaemic B cells in patients from the different histopathological groups Results are shown in Table I . (Table II) .
(ii) Peanut agglutinin binding. Of 45 patients with FCC tumour analysed for this marker, 10 had more than 5% PNA positive cells. Five of these did not have overt B cell leukaemia. Occasional patients with other types of B cell tumour also had >5% PNA positive cells including the patient with plasma cell leukaemia (Figure 2 ).
(iii) HLA-DR alpha chain expression. Cells from only one of 37 patients with diffuse lymphocytic lymphoma failed to express this antigen. It was expressed on the neoplastic B cells found in the blood in all of the 14 cases with FCC tumours.
Non-B cells in patients with B cell lymphopenia
The number of cells binding SRBC and anti-T3 antigen-coated ox cells was analysed in relation to the number of B cells in aleukaemic patients to see if the absolute B cell lymphopenia, which was a feature of many patients in this series, was associated with reduced T cell numbers. Of the 18 patients with follicle centre cell lymphoma and B cell lymphopenia (<0.1 x 10'11), eleven were judged to be T lymphopenic in that they had fewer than 0.6 x 109-1 1 cells binding SRBC. In high grade lymphoma 7 out of 11 B lymphopenic patients were T lymphopenic. T cell lymphopenia was seen in 3/11 patients with B lymphopenia in myelomatosis and in 4/7 with lymphoplasmacytoid lymphoma. Overall 53% of 47 patients with B cell lymphoma had reduced number of T cells. Only 4 cases of selective T cell lymphopenia were identified in Ill cases of B cell neoplasia without overt B cell leukaemia. The incidence of lymphopenia and lymphocytosis in patients without B cell leukaemia is shown in Table III . Only 3/108 patients in this table had lymphocyte counts above the 95 percentile for adults. Lymphopenia, however, was a common feature of all patient groups. Table III also shows the frequency with which patients presented with null cell numbers >0.5 x 109-1. This was no greater in the non-Hodgkin's lymphoma groups than in a healthy adult control group assessed using the same techniques during the period of this study.
The incidence of raised null cell numbers was slightly higher in myelomatosis compared to that in healthy controls. However, this difference was not significant (P>0.05 Wilcoxan sum of ranks test).
Discussion
Immunological methods have identified several patients with a B cell leukaemia which would not have been suspected from conventional haematological tests. Diffuse lymphocytic lymphoma with the histological appearances in secondary lymphoid organs associated with B-CLL (ML-BCLL) is most frequently associated with overt haematologically recognisable lymphocytic leukaemia. This is much less frequently a feature in other B cell neoplasms. It has been recognised, however, that a proportion of these patients at some stage of their illness develop a B cell leukaemia indistinguishable from that associated with CLL. Galton et al. (1978) followed up 75 patients with follicle centre cell lymphoma over a period of 20 years and found that several patients in this group had a lymphocytosis resembling that found in CLL. Seventeen out of 75 cases in his study had lymphocyte counts ranging from 5-30 x 109 1 and in 8 others, although the count was <5 x 109 1-1, the bone marrow showed lymphocytic infiltration. Cells with notched or cleaved nuclei were seen in the peripheral blood of 8 of the cases seen in their study. Garrett et al. (1979) studied 63 patients with non-Hodgkin's lymphoma all with lymphocyte counts below 6 x 109 1 1 and correlated peripheral blood findings with the histology using inbalance in kappa/lambda ratio to determine the presence of an abnormal clone of lymphocytes. In their study, 81% of cases of well differentiated diffuse lymphoma, 66% of poorly differentiated diffuse lymphoma and 22% of diffuse histiocytic lymphoma had cells of the abnormal clone in the peripheral blood. GajlPeczalska et al. (1975) The technique of mouse erythrocyte rosetting is described in the methods and did not involve neuraminidase-treatment of cells. (Coutino et al., 1980) ; The possibility that such an evocative process occurs in myelomatosis has not been excluded. Preud'homme et al. (1977) have described the appearance of T cells in the blood of a patient with myelomatosis bearing epitopes on non-immunoglobulin molecules common with VH determinants on the paraprotein. This also may represent an example of expansion of non-neoplastic cells via the idiotype network. (Rubinstein et al., 1982) . In only one of the cases of myelomatosis which we studied (excluding the case of plasma cell leukaemia) was there lymphocytosis. In this patient the rise was associated with an increase in blood null cell members to 1.9 x 1091 (Table III) .
It is relevant to consider how neoplasms with associatedc B cell leukaemia can exist at more than one stage of differentiation. One hypothesis is that neoplastic transformation in patients with B cell leukaemia occurs at the virgin B cell level (Johnstone, 1982) . Alternatively, the neoplastic transformation may take place in an activated B cell i.e. an immunoblast. These cells can give rise to both more mature forms and memory B cells which form part of the recirculating small B cell pool. Memory B cells have been shown to develop from a small proportion of immunoblasts in efferent lymph (Howard, 1972) . Equally there is good evidence that centroblasts of germinal centres may give rise to memory small B cells (Klaus et al., 1980) . This finding opens the possibility that the leukaemia associated with follicle centre cell tumours could reflect the physiological production of memory B cells from germinal centres. Similarly it can be argued plausibly that patients with lymphoplasmacytoid tumours and B cell leukaemia have neoplastic immunoblasts capable of generating three cell types. i.e. (1) self replication (2) memory B cell formation and (3) lymphoplasmacytoid cell formation. Presumably the neoplastic process has resulted in loss of a self-limiting component in the first of these compartments. In the case of myelomatosis it would appear that the clonogenic cells are capable of self replication and bone marrow seeking plasma cell formation but lack the capacity to generate memory B cells.
Apart from SmIg, the MRBC (mouse) and HLA-DR markers have been found useful in diagnosis of B cell neoplasms. Our findings confirm that the most prominent binding of mouse red cells is seen in CLL (Catovsky et al. 1979 and Koziner et al. 1977) . Catovsky et al. (1979) report higher proportions of cells binding to mouse cells in B CLL than we have found. This probably reflects the use of neuraminidase pretreatment of cells before rosetting which has been reported as selectively increasing mouse rosettes in CLL (Catovsky et al., 1976) . Mouse rosette binding has been reported not to be a feature of prolymphocytic leukaemia (Catovsky et al., 1979) . However, Koziner et al. (1980) reported four cases with the features of prolymphocytic leukaemia whose neoplastic cells did bind mouse red cells. In the current study mouse rosetting was not found in the four cases of B-prolymphocytic leukaemia studied. The spectrum of patients studied by us with ML-BCLL probably includes a higher proportion of patients with low lymphocyte count than most previous studies which tend to concentrate on classical CLL with blood lymphocyte counts > 10 x 1091-'. We were unable to identify any feature using the marker range reported in this study which distinguished the phenotype of low and high blood lymphocyte count ML-BCLL. The HLA-DR marker is useful in that B cells at the late differentiation stage, including lymphoplasmacytoid cells, are DR negative whereas cells at the B cell stage, whether pre-or postantigen stimulation, are DR positive. Peanut agglutinin hgs been reported to bind to germinal centre cells (Rose et al., 1981) . However, this has not proved in our hands to be a useful marker for B cell leukaemia associated with FCC tumours. This finding supports the concept that leukaemic B cells in this disease, in many cases, represent a distinct maturation phase from the tumour cells found in secondary lymphoid organs. It is arguable whether they are a precursor or a derivative of the follicle centre cells. Positive results for cells bearing PNA receptors have been observed in acute lymphoblastic leukaemia (Levin et al., 1980) and for a blood cell subset which lacks HLA (Ballet, 1980) . PNA has also been reported to be a marker for normal and leukaemic cells of the monocyte lineage (O'Keefe and Ashman, 1982) .
Total lymphopenia as well as B cell lymphopenia was found in a significant proportion of patients in most of the different histopathological groups of B cell lymphoma. This was most obvious in patients with FCC lymphoma or high grade lymphoma where one-third and over half of the respective cases had B cell lymphopenia at presentation. The significance of this lymphopenia in B cell neoplasia is not known but it has been noted by other investigators (Bums et al., 1979; Dillman et al., 1981) . It is sufficiently common to be a diagnostic pointer to non-Hodgkin's lymphoma. However, it is also associated with other disorders such as primary immunodeficiency, which may present with features resembling lymphoma.
